Phibro Animal Health (NASDAQ:PAHC) Rating Increased to Neutral at BNP Paribas Exane

BNP Paribas Exane upgraded shares of Phibro Animal Health (NASDAQ:PAHC - Free Report) from an underperform rating to a neutral rating in a research report sent to investors on Monday, MarketBeat reports. BNP Paribas Exane currently has $24.00 price target on the stock.

A number of other brokerages also recently commented on PAHC. Morgan Stanley increased their price objective on shares of Phibro Animal Health from $20.00 to $21.00 and gave the company an "equal weight" rating in a research report on Thursday, May 8th. Wall Street Zen raised Phibro Animal Health from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $20.80.

Phibro Animal Health Stock Down 1.1%

Phibro Animal Health stock traded down $0.26 during mid-day trading on Monday, reaching $24.45. 275,477 shares of the company's stock were exchanged, compared to its average volume of 206,558. The company has a quick ratio of 1.23, a current ratio of 2.91 and a debt-to-equity ratio of 2.67. Phibro Animal Health has a twelve month low of $16.16 and a twelve month high of $26.55. The company has a market cap of $990.96 million, a P/E ratio of 31.35, a P/E/G ratio of 0.47 and a beta of 0.74. The company has a fifty day moving average of $21.39 and a 200-day moving average of $21.89.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.52 by $0.11. The firm had revenue of $347.80 million during the quarter, compared to analyst estimates of $352.41 million. Phibro Animal Health had a return on equity of 30.51% and a net margin of 2.68%. Sell-side analysts expect that Phibro Animal Health will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 25th. Investors of record on Wednesday, June 4th will be given a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, June 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.96%. Phibro Animal Health's dividend payout ratio (DPR) is presently 61.54%.

Institutional Investors Weigh In On Phibro Animal Health

Large investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in Phibro Animal Health during the 4th quarter worth $29,000. National Bank of Canada FI acquired a new stake in shares of Phibro Animal Health during the first quarter worth about $30,000. Lazard Asset Management LLC increased its position in Phibro Animal Health by 2,739.7% in the 4th quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock valued at $34,000 after acquiring an additional 1,589 shares during the period. Aquatic Capital Management LLC acquired a new position in Phibro Animal Health in the 4th quarter valued at about $69,000. Finally, Virtus Fund Advisers LLC purchased a new stake in shares of Phibro Animal Health in the fourth quarter valued at about $69,000. 99.34% of the stock is owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.